Comparable stake leader
GLAZER CAPITAL, LLC
SEC ownership of Inozyme Pharma, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001693011.
Disclosed value leader
Longitude Capital Partners III, LLC
Comparable rows
4/17
Latest evidence
01 Jul 2025
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
GLAZER CAPITAL, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
4 of 17
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
GLAZER CAPITAL, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
01 Jul 2025
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001693011
- Issuer location
- Boston, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Inozyme Pharma, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
GLAZER CAPITAL, LLC
Disclosed value leader
Longitude Capital Partner...
Comparable rows
4/17
Latest evidence
01 Jul 2025
13D/G
3/4/5
Lead comparable stake: 6.6%
13 rows are not safely comparable across share classes.
13D/G row: GLAZER CAPITAL, LLC
Showing 1-8 of 17 holder rows.
Quick read
GLAZER CAPITAL, LLC leads the comparable SEC ownership view at 6.6%.
4 of 17 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens GLAZER CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 4
GLAZER CAPITAL, LLC
6.6%
BlackRock, Inc.
4.1%
EVENTIDE ASSET MANAGEMENT, LLC
3.5%
Affinity Asset Advisors, LLC
2.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 17 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| GLAZER CAPITAL, LLC |
13D/G
|
6.6%
|
$5,017,289
4,251,940 shares
|
$0 | 28 May 2025 |
| BlackRock, Inc. |
13D/G
|
4.1%
|
$10,654,712
2,663,678 shares
|
$0 | 30 Jun 2025 |
| EVENTIDE ASSET MANAGEMENT, LLC |
13D/G
|
3.5%
|
$2,353,200
2,220,000 shares
|
$0 | 31 Dec 2024 |
| Affinity Asset Advisors, LLC |
13D/G
Affinity Healthcare Fund, LP
|
2.9%
|
$2,203,898
1,867,710 shares
|
$0 | 20 May 2025 |
| Longitude Capital Partners III, LLC |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$14,902,533
4,174,379 shares
|
— | 19 Apr 2022 |
| Pivotal bioVenture Partners Fund I, L.P. |
3/4/5
Director
|
—
class O/S missing
|
$5,611,115
1,571,741 shares
|
— | 01 Aug 2023 |
| Henric Bjorn Bjarke |
3/4/5
SVP, COO
|
—
class O/S missing
|
$376,424
105,441 shares
|
— | 15 Dec 2022 |
| Matthew Winton |
3/4/5
COO
|
— |
$184,675
|
— | 01 Jul 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 05 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to Inozyme Pharma, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Largest Forms 3/4/5 holder
Longitude Capital Partners III, LLC
Net 12M change
$0
Latest report
01 Jul 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Longitude Capital Partners III, LLC | 10%+ Owner | $14,902,533 | Mixed | 19 Apr 2022 | ||
| Pivotal bioVenture Partners Fund I, L.P. | Director | $5,611,115 | Mixed | 01 Aug 2023 | ||
| Henric Bjorn Bjarke | Svp, Coo | $376,424 | Mixed | 15 Dec 2022 | ||
| Matthew Winton | Coo | $184,675 | Mixed | 01 Jul 2025 | ||
| Sanjay Subramanian | SVP, CFO & Head of BD | $171,325 | Mixed | 01 Jul 2025 | ||
| Douglas A. Treco | CEO & Chairman, Director | $38,500 | Mixed | 01 Jul 2025 | ||
| Robert Lorne Hopfner | Director | $0 | Mixed | 01 Jul 2025 | ||
| Axel Bolte | Director | $0 | Mixed | 01 Jul 2025 | ||
| Lynne Marie Sullivan | Director | Mixed | 01 Jul 2025 | |||
| Erik Harris | Director | Mixed | 03 Oct 2024 | |||
| Inozyme Pharma, Inc. | Director | Mixed | 23 Jun 2021 | |||
| Mathers Edward T. | Director | Mixed | 18 Jun 2024 | |||
| Reinaldo M. Diaz | Director | Mixed | 18 Jun 2024 | |||
| Martin Edwards | Director | Mixed | 18 Jun 2024 | |||
| Sarah M. Bhagat | Director | Mixed | 18 Jun 2024 | |||
| Stephen J. DiPalma | Interim CFO | Mixed | 17 May 2021 |
Recent insider transactions for Inozyme Pharma, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.